You can read some of the February 19th print issue of Chain Drug Review in here. In CDR’s digital editions, you can find special sections and additional pages not posted online. You will need to register, but subscription is free!
NEW YORK — The Agile Innovation Series focuses on the need for organizations to constantly evolve and innovate with an agile mind-set to remain viable in today’s dynamic world. Throughout the series accelerate360’s Trey Holder explores the current business environment through interviews with leaders in a variety of fields. This month, Holder caught up with
KANSAS CITY — In 2024, Hallmark will continue to build on the popularity of Hallmark + Venmo Cards. These new cards offer a unique and convenient way of gifting to friends and family. “With this recently launched, first-of-its kind collaboration, customers can now securely send money with Venmo in a physical Hallmark card. By bringing
Younger adults don’t have a corner on the tech market — far from it. A new AARP survey finds that older Americans are about as likely as those under age 50 to own a smartphone, tablet or other device. Nearly nine out of 10 Americans (89% of those 50-plus and 90% of those 18 to
Lindsay Proffitt, who runs the private label over-the-counter drug business at Dr. Reddy’s, spoke with Chain Drug Review about her role, the significance of store brands for the company and the opportunities they present. CDR: What is your title and what are your responsibilities? PROFFITT: My title is head of private label O-T-C product management,
“The future is purchased by the present,” wrote Samuel Johnson in one of his essays for The Rambler. That idea was reflected during a panel discussion at last month’s FMI Midwinter Conference. Members of the group — which included David Best, president and chief operating officer of Coborn’s Inc.; Sandy Douglas, chief executive officer of
On the eve of the annual NACDS regional chain conference, about to convene in South Florida as this piece is written, now is perhaps the perfect time to reflect on the stunning success regional drug chains are experiencing in the U.S. chain drug community. For openers, it is simpler to evaluate the small chain segment
The chemical and materials industry contributes roughly $5.7 trillion to global GDP (gross domestic product) and supports an estimated 120 million jobs, according to a recent report published by the International Council of Chemical Associations. To meet massive demand, chemicals and materials research and development teams face many challenges, including the need to move at
